AJCC第8版III期黑色素瘤中枢神经系统转移的累积发生率与预测因素
该研究基于美国和澳大利亚两个黑色素瘤中心的1,918例AJCC第8版III期黑色素瘤患者,计算中枢神经系统转移的累积发生率(考虑竞争风险),并分析预测因素。中位随访70.2个月,1年、2年、5年累积发生率分别为3.6%、9.6%、15.8%。患者性别、年龄、AJCC分期、原发灶部位及核分裂率显著影响风险,高核分裂率与各时间点风险增加相关。
要点
- III期黑色素瘤5年CNS转移累积发生率为15.8%。
- 原发灶核分裂率高与CNS转移风险增加显著相关。
- 性别、年龄、AJCC分期和原发灶部位也影响CNS转移风险。
核心结论
- 两个地理区域不同的大队列中III期黑色素瘤的CNS转移发生率相似。
- 原发肿瘤核分裂率的重要性突出,为制定循证监测策略和评估辅助治疗影响提供框架。
研究设计与样本
- 回顾性队列研究,纳入1998-2014年诊断的1,918例AJCC第8版III期黑色素瘤患者,基线CNS影像阴性(诊断4个月内),数据来自美国和澳大利亚两个中心。
- 采用竞争风险方法计算CNS转移累积发生率,从III期诊断时及诊断后1、2、5年基准时间点评估。
主要发现
- 中位随访70.2个月,711例(37.1%)发生远处复发。
- 首次远处转移部位:仅CNS占3.9%,CNS和颅外(EC)占1.8%,仅EC占31.4%。
- 随访期间16.7%患者诊断为CNS转移。
- CNS转移累积发生率:1年3.6%(95%CI 2.9%-4.6%),2年9.6%(95%CI 8.3%-11.0%),5年15.8%(95%CI 14.1%-17.6%)。
- 多因素和条件分析显示,患者性别、年龄、AJCC分期、原发肿瘤部位和原发肿瘤核分裂率显著影响CNS转移风险;高核分裂率与诊断时及所有后续时间点CNS转移风险增加显著相关。
临床怎么用
- 基于CNS转移累积发生率和预测因素(尤其是核分裂率),可辅助制定III期黑色素瘤患者的CNS监测策略。
- 需评估当代辅助治疗对CNS转移风险的影响。
局限性
- 回顾性研究设计,数据来自两个中心,可能存在选择偏倚。
- 基线CNS影像阴性要求可能限制人群代表性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Improved understanding of the incidence, risk factors, and timing of CNS metastasis is needed to inform surveillance strategies for patients with melanoma. PATIENTS AND METHODS: Clinical data were extracted from the databases of 2 major melanoma centers in the United States and Australia for 1,918 patients with American Joint Committee on Cancer (AJCC) 8th edition stage III melanoma, diagnosed from 1998-2014, who had (negative) baseline CNS imaging within 4 months of diagnosis. The cumulative incidence of CNS metastasis was calculated in the presence of the competing risk of death, from stage III presentation and at benchmark time points 1, 2, and 5 years postdiagnosis. RESULTS: At a median follow-up of 70.2 months, distant recurrence occurred in 711 patients (37.1%). The first site of distant metastasis was CNS only for 3.9% of patients, CNS and extracranial (EC) for 1.8%, and EC only for 31.4%. Overall, 16.7% of patients were diagnosed with CNS metastasis during follow-up. The cumulative incidence of CNS metastasis was 3.6% (95% CI, 2.9% to 4.6%) at 1 year, 9.6% (95% CI, 8.3% to 11.0%) at 2 years, and 15.8% (95% CI, 14.1% to 17.6%) at 5 years. The risk of CNS metastasis was significantly influenced by patient sex, age, AJCC stage, primary tumor site, and primary tumor mitotic rate in multivariable and conditional analyses. High primary tumor mitotic rate was significantly associated with increased risk of CNS metastasis at diagnosis and all subsequent time points examined. CONCLUSION: Similar rates of CNS metastasis were observed in 2 large, geographically distinct cohorts of patients with stage III melanoma. The results highlight the importance of primary tumor mitotic rate. Furthermore, they provide a framework for developing evidence-based surveillance strategies and evaluating the impact of contemporary adjuvant therapies on the risk of CNS metastasis development.
引用
- Haydu LE, Lo SN, McQuade JL, et al. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol. 2020. PMID: 31990608. doi:10.1200/JCO.19.01508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。